Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Alm

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Clinical Pharmacology and Therapeutics|September 8, 2000
Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotypeK Herrlin, A Y Massele, G Rimoy, et al.
Journal of Clinical Pharmacy and Therapeutics|April 5, 2001
Comparative in vitro and in vivo study of a sugar-coated chloroquine preparation marketed in Tanzania versus an ordinary brandS E Nsimba, Y Aden-Abdi, G Rimoy, et al.
Clinical Pharmacology and Therapeutics|December 2, 1998
Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitorsE Arlander, G Ekström, C Alm, et al.
European Journal of Clinical Pharmacology|January 1, 1993
Polymorphic 2-hydroxylation of desipramine. A population and family studyM L Dahl, L Iselius, C Alm, et al.
British Journal of Clinical Pharmacology|December 1, 1996
Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humansY Böttiger, P Dostert, M S Benedetti, et al.
PM & R : the Journal of Injury, Function, and Rehabilitation|July 30, 2024
Curricula for training advanced practice providers as part of the physiatrist-led teamJoseph E Burris, John C Alm, Steven L Gershon, et al.
British Journal of Clinical Pharmacology|November 1, 1994
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine testL Bertilsson, J A Carrillo, M L Dahl, et al.
Pharmacogenetics|January 14, 2000
Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotypeA Wennerholm, I Johansson, A Y Massele, et al.
Clinical Pharmacology and Therapeutics|November 3, 1998
Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotypeK Herrlin, A Y Massele, M Jande, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Clinical Pharmacology and Therapeutics|September 8, 2000
Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotypeK Herrlin, A Y Massele, G Rimoy, et al.
Journal of Clinical Pharmacy and Therapeutics|April 5, 2001
Comparative in vitro and in vivo study of a sugar-coated chloroquine preparation marketed in Tanzania versus an ordinary brandS E Nsimba, Y Aden-Abdi, G Rimoy, et al.
Clinical Pharmacology and Therapeutics|December 2, 1998
Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitorsE Arlander, G Ekström, C Alm, et al.
European Journal of Clinical Pharmacology|January 1, 1993
Polymorphic 2-hydroxylation of desipramine. A population and family studyM L Dahl, L Iselius, C Alm, et al.
British Journal of Clinical Pharmacology|December 1, 1996
Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humansY Böttiger, P Dostert, M S Benedetti, et al.
PM & R : the Journal of Injury, Function, and Rehabilitation|July 30, 2024
Curricula for training advanced practice providers as part of the physiatrist-led teamJoseph E Burris, John C Alm, Steven L Gershon, et al.
British Journal of Clinical Pharmacology|November 1, 1994
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine testL Bertilsson, J A Carrillo, M L Dahl, et al.
Pharmacogenetics|January 14, 2000
Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotypeA Wennerholm, I Johansson, A Y Massele, et al.
Clinical Pharmacology and Therapeutics|November 3, 1998
Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotypeK Herrlin, A Y Massele, M Jande, et al.
Pageof 4